Qiao Yuan, Xie Dong, Li Zhengxiang, Cao Shaohua, Zhao Dong
Department of Clinical Pharmacy, Yan'an University Affiliated Hospital, Yan'an, Shaanxi, China.
Department of Pharmacy, Tianjin Medical University General Hospital, Tianjin, China.
Hum Vaccin Immunother. 2025 Dec;21(1):2435598. doi: 10.1080/21645515.2024.2435598. Epub 2025 Jan 8.
The global burden of cancer continues to grow, posing a significant public health challenge. Although cancer immunotherapy has shown significant efficacy, the response rate is not high. Therefore, the objective of our research was to identify the latest research trends and hotspots on biomarkers from 1993 to 2023. Data were collected from the database Web of Science core collection. Bibliometric analysis and visualization were conducted with CiteSpace(6.3.1), VOSviewer (v1.6.20), R-bibliometrix(v4.3.3), and Microsoft Excel(2019). A total of 2686 literatures were retrieved. The sheer annual volume of publications has shown a rapid upward trend since 2015. The United States has generated the most publications and Harvard University ranked as a leading institution. The global biomarker research on immune checkpoint inhibitors (ICIs) revealed regional differences and in-depth explorations should be promoted in developing countries. Although China has become the second largest country in terms of publication, the average citation per paper and the total link strength were both lower than the other countries. The research on biomarkers mainly concentrated upon the following aspects: PD-1/PD-L1, CTLA-4, gene expression, adverse events, total mutational burden (TMB), body mass index (BMI), gut microbiota, cd8(+)/cd4(+) t-cells, and blood-related biomarkers such as lactate dehydrogenase (LDH), neutrophil-lymphocyte ratio (NLR), cytokines. Furthermore, "artificial intelligence" and "machine learning" have become the most important research hotspot over the last 2 y, which will help us to identify useful biomarkers from complex big data and provide a basis for precise medicine for malignant tumors.
癌症的全球负担持续增长,构成了重大的公共卫生挑战。尽管癌症免疫疗法已显示出显著疗效,但有效率并不高。因此,我们研究的目的是确定1993年至2023年生物标志物的最新研究趋势和热点。数据从科学网核心合集数据库收集。使用CiteSpace(6.3.1)、VOSviewer(v1.6.20)、R-bibliometrix(v4.3.3)和Microsoft Excel(2019)进行文献计量分析和可视化。共检索到2686篇文献。自2015年以来,出版物的年总量呈快速上升趋势。美国发表的文献最多,哈佛大学是领先机构。全球免疫检查点抑制剂(ICI)的生物标志物研究存在地区差异,发展中国家应加强深入探索。尽管中国已成为发表量第二大国,但每篇论文的平均被引次数和总链接强度均低于其他国家。生物标志物的研究主要集中在以下方面:PD-1/PD-L1、CTLA-4、基因表达、不良事件、总突变负担(TMB)、体重指数(BMI)、肠道微生物群、cd8(+)/cd4(+) T细胞以及血液相关生物标志物,如乳酸脱氢酶(LDH)、中性粒细胞与淋巴细胞比值(NLR)、细胞因子。此外,“人工智能”和“机器学习”在过去两年已成为最重要的研究热点,这将有助于我们从复杂的大数据中识别有用的生物标志物,为恶性肿瘤的精准医疗提供依据。